US FDA grants fast track status to Aura Biosciences belzupacap sarotalocan to treat NMIBC

Aura Biosciences, Inc., a clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura